MeOmics, transforming mental healthcare

MeOmics' mission is to improve the diagnosis and treatment of mental health illnesses through combining unique neuronal cell assays and data-rich descriptors of individual patients including genomics.

This will allow preclinical screening, before expensive phase III drug trials, and will also enable clinical screening of patients leading to personalised mental healthcare, shortening the time and cost to better patient outcomes.
MeOmics have proved the technology in an academic setting and have recently secured pre-seed funding through angel investors and grant funding (InnovateUK's Biomedical Catalyst competition).

We are now seeking seed funding to progress the scale-up, collect more patient samples and increase the throughput of our unique process and technology.

MeOmics are an exciting biotech start-up, on a socially important mission, with very high growth potential.